Have a personal or library account? Click to login
COVID-19: Some Pathophysiological and Endocrine Aspects Cover

COVID-19: Some Pathophysiological and Endocrine Aspects

Open Access
|Dec 2022

References

  1. 1. World Health Organization. Coronavirus disease 2019 (COVID-19). Situation report – 51. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200816-covid-19-sitrep-209.pdf
  2. 2. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-CoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4)536-44.10.1038/s41564-020-0695-z709544832123347
  3. 3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223): 507-13.10.1016/S0140-6736(20)30211-7713507632007143
  4. 4. Lu R, Zhao X, Li J, Niu P, Bo J, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224): 565-74.10.1016/S0140-6736(20)30251-8715908632007145
  5. 5. Forster P, Forster L, Renfrew C, Forster M. Phylogenetic network analysis of SARSCoV-2 genomes. Proc Natl Acad Sci USA 2020;117(17):9241-43.10.1073/pnas.2004999117719676232269081
  6. 6. Li F. Structure, function and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3(1):237–61.10.1146/annurev-virology-110615-042301545796227578435
  7. 7. Walls A, Park Y, Tortorici M, Wall A, McGuire A, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281-92.10.1016/j.cell.2020.02.058710259932155444
  8. 8. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARSCoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;181(2):271-80.10.1016/j.cell.2020.02.052710262732142651
  9. 9. Rockx B, Kuiken T, Herfst S, Bestebroer T, Lamers MM, Oude Munnink BB, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science. 2020;368(6494):1012-15.10.1126/science.abb7314716467932303590
  10. 10. Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251-54.10.1038/nature12005709532623486063
  11. 11. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-37.10.1002/path.1570716772015141377
  12. 12. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol. 2013;216(2):R1-R17.10.1530/JOE-12-034123092879
  13. 13. Guy JL, Lambert DW, Warner FJ, Hooper NM, Turner AJ. Membrane-associated zinc peptidase families: comparing ACE and ACE2. Biochim Biophys Acta. 2005;1751(1):2-8.10.1016/j.bbapap.2004.10.010710524316054014
  14. 14. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100(14):8258-63.10.1073/pnas.143286910016621612829792
  15. 15. Horiuchi M, Akishita M, Dzau V. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999;33–2№:613-21.10.1161/01.HYP.33.2.613
  16. 16. Kuba K, Imai Y, Ohto-Nakanishi T, Penninger J. Trilogy of ACE2: a peptidase in the reninangiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther. 2010;128(1):119-28.10.1016/j.pharmthera.2010.06.003711267820599443
  17. 17. Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):422-26.10.1186/s13054-020-03120-0735613732660650
  18. 18. Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007;170(4):1136-47.10.2353/ajpath.2007.061088182944817392154
  19. 19. Alsaad KO, Hajeer AH, Al Balwi M, Al Moaiqel M, Al Oudah N, Al Ajlan A, et al. Histopathology of Middle East Respiratory Syndrome coronovirus (MERS-CoV) infection-clinicopathological and ultrastructural study. Histopathology. 2018;72(3):516-24.10.1111/his.13379716551228858401
  20. 20. Wei L, Sun S; Zhang J; Zhu H; Xu Y; Ma Q, et al. Endocrine cells of the adenohypophysis in severe acute respiratory syndrome (SARS). Biochem Cell Biol. 2010;88(4):723-30.10.1139/O10-02220651845
  21. 21. Lisco G, Tullio A, Stragapede A, Solimando A, Albanese F, Capobianco М, et al. COVID-19 and the Endocrine System: A Comprehensive Review on the Theme. J Clin Med.2021;10(13):2920-27.10.3390/jcm10132920826933134209964
  22. 22. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327-31.
Language: English
Page range: 112 - 117
Submitted on: Mar 10, 2022
|
Accepted on: Aug 5, 2022
|
Published on: Dec 13, 2022
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2022 Katya N. Todorova, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.